...
首页> 外文期刊>British Journal of Cancer >Tamoxifen metabolism: pharmacokinetic and in vitro study
【24h】

Tamoxifen metabolism: pharmacokinetic and in vitro study

机译:他莫昔芬代谢:药代动力学和体外研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The qualitative and quantitative importance of tamoxifen (TMX) metabolism in vivo led us to investigate further the metabolic profile of this major anti-oestrogenic drug in a significant group of 81 breast cancer patients and to evaluate the respective in vitro activity of each metabolite. TMX and its four metabolites described until now (NDT, 4-OHT, Y, Z) were measured in blood (HPLC method) at the time of first drug intake and at the steady state. Between these two states, the unchanged drug relative proportion dropped from 65% to 27%. Demethylation was the major metabolic pathway. For 13 clinically evaluable patients, there was no significant difference in the distribution of serum levels of TMX and metabolites as a function of response to treatment. In vitro studies were performed on two human breast cancer cell lines: MCF-7, oestrogen receptor and progesterone receptor positive (ER+, PR+) and CAL-18 B (ER-, PR-). Cytostatic effects were evaluated by the tritiated thymidine incorporation test. TMX and all metabolites were active on these two cell lines, but the 50% inhibitory concentrations (IC50) were 4-250-fold higher in CAL-18 B than in MCF-7, depending on the metabolite considered. For the MCF-7 cells only, the antiproliferating activity was parallel to the relative binding affinity for ER. Moreover, for the MCF-7 cells only, the effects of these drugs were partially reversed by oestradiol (E2), the higher the metabolite affinity for ER, the lower the reversal efficacy. These compounds were tested in mixtures at proportions duplicating those found in patients after initial drug intake (mixture D1), and the steady state (mixture Css). The mixtures were also compared to the equimolar unchanged drug. No differences were seen among these three experimental conditions for either MCF-7 or CAL-18 B. A dose-effect relationship was noted. Overall, TMX and its metabolites exert a dual effect: when concentrations are below a threshold between 2 x 10(-6) and 10(-5) M, the drugs are mainly cytostatic; this effect is related to their affinity for ER. At higher relevant clinical concentrations, a cytotoxic activity is observed and it appears independent of the presence of ER.
机译:他莫昔芬(TMX)体内代谢在质量和数量上的重要性使我们进一步研究了这一主要抗雌激素药物在81名乳腺癌患者中的代谢组,并评估了每种代谢物的体外活性。首次服用药物时和稳态时,在血液中(HPLC法)测量了迄今为止描述的TMX及其四种代谢物(NDT,4-OHT,Y,Z)。在这两种状态之间,未改变的药物相对比例从65%降至27%。去甲基化是主要的代谢途径。对于13位临床上可评估的患者,TMX和代谢产物的血清水平分布对治疗反应没有显着差异。在两种人类乳腺癌细胞系上进行了体外研究:MCF-7,雌激素受体和孕激素受体阳性(ER +,PR +)和CAL-18B(ER-,PR-)。通过the化胸苷掺入试验评估细胞抑制作用。 TMX和所有代谢物在这两个细胞系中均具有活性,但取决于所考虑的代谢物,CAL-18 B中50%抑制浓度(IC50)比MCF-7高4-250倍。仅对于MCF-7细胞,抗增殖活性与对ER的相对结合亲和力平行。而且,仅对于MCF-7细胞,这些药物的作用被雌二醇(E2)部分逆转,代谢产物对ER的亲和力越高,逆转功效越低。对这些化合物的混合比例进行了测试,其比例与首次服用药物(混合物D1)和稳态(混合物Css)后在患者中发现的比例相同。还将混合物与等摩尔不变药物进行比较。对于MCF-7或CAL-18 B,在这三个实验条件之间均未观察到差异。注意到剂量效应关系。总的来说,TMX及其代谢产物具有双重作用:当浓度低于2 x 10(-6)和10(-5)M之间的阈值时,药物主要具有抑制细胞生长的作用;这种作用与其对ER的亲和力有关。在较高的相关临床浓度下,观察到了细胞毒性活性,并且它似乎与ER的存在无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号